Skip to main content
. 2020 Nov 6;8(21):5172–5179. doi: 10.12998/wjcc.v8.i21.5172

Table 4.

Comparison of survival and progression-free survival between the two groups

Follow-up results
S-1 group (n = 47)
Gemcitabine group (n = 47)
t
P value
Progress-free survival (mo) 6.63 (1.02) 6.25 (0.94) 1.878 0.064
Survival (mo) 13.63 (1.52) 13.02 (1.45) 1.991 0.050